Clinical impact of ibrutinib plus R-CHOP in untreated DLBCL co-expressing BCL2 and MYC in the phase 3 PHOENIX trial View External Link Categories Peer Reviewed Publications Topics: clinical trial DLBCL COO ibrutinib Phase III PHOENIX trial R-CHOP